TAmiRNA

Founded in 2013, TAmiRNA specializes in the analysis of cell-free RNAs (cfRNAs), with a particular focus on microRNAs, to support the development of in-vitro diagnostic assays based on cfRNA signatures. The company’s technologies have enabled the development of several minimally invasive diagnostic tests, including the CE-IVD-certified hepatomiR® assay for evaluating liver function.    

TAmiRNA provides comprehensive RNA analysis services for academic and industrial research, encompassing transcriptomic profiling of liquid biopsies, extracellular vesicles (EVs), cells, and tissues. Expertise includes the analysis of both non-coding and messenger RNAs, with optimized workflows tailored to challenging sample types such as formalin-fixed paraffin-embedded (FFPE) tissues, biofluids (serum, plasma, urine, cerebrospinal fluid, saliva), and EVs.    

The company’s approach integrates advanced wet-lab methods with customized bioinformatics pipelines, ensuring robust and reproducible data generation. A key strength of TAmiRNA’s service is the provision of expert consultancy and detailed bioinformatics support to deliver high-quality, publication-ready results.